20.47
0.14 (0.69%)
0.14 (0.69%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Allogene Therapeutics Inc | ALLO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.14 | 0.69% | 20.47 | 20.15 | 20.745 | 20.57 | 20.33 | 11:25:38 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 20.44 | 20.50 | 0.06 | 0.29% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 629 | 50,833 | $ 20.51 | $ 1,042,733 | 823,418 | 17.43 - 33.80 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 11:25:38 | 100 | $ 20.47 | USD |
Allogene Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 2.56B | 124.91M | $ -211.81M | -1.82 | - | 120.86M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 10.00 | 3.30% |
Allogene Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALLO Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 18.98 | 22.29 | 17.79 | 19.49 | 602,516 | 1.49 | 7.85% |
| 1 Month | 25.56 | 26.13 | 17.43 | 20.16 | 772,596 | -5.09 | -19.91% |
| 3 Months | 26.15 | 28.30 | 17.43 | 22.96 | 677,001 | -5.68 | -21.72% |
| 6 Months | 26.71 | 33.39 | 17.43 | 25.14 | 598,677 | -6.24 | -23.36% |
| 1 Year | 27.93 | 33.80 | 17.43 | 26.39 | 501,653 | -7.46 | -26.71% |
| 3 Years | 22.00 | 35.55 | 17.43 | 26.61 | 533,721 | -1.53 | -6.95% |
| 5 Years | 22.00 | 35.55 | 17.43 | 26.61 | 533,721 | -1.53 | -6.95% |
Allogene Therapeutics Description
| Allogene Therapeutics Inc is the United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies. |
